Hematological Disorders

A clinical trial demonstrated that bezuclastinib significantly improved symptoms and biomarkers of systemic mastocytosis.

Patients with systemic mastocytosis (SM) showed promising overall response rates to treatment with bezuclastinib, its maker announced.

Preliminary results showed that patients receiving bezuclastinib had better results than patients receiving a placebo in a clinical trial.

Imatinib is a treatment for patients with aggressive SM without the KIT D816V mutation or having unknown KIT mutational status.

A recent study assessed the current state of treatments for advanced systemic mastocytosis and the promise of future ones.

Brain fog caused by SM can be debilitating, but fortunately, there are ways to manage it and reduce its effect on your daily life.

A clinical trial studying bezuclastinab in SM patients has shown positive preliminary results in part one of phase 2.

The phase 2 Apex trial aiming to test bezuclastinib in patients with SM, has recently completed enrollment for part one of the trial.

A clinical trial assessing the efficacy of bezuclastinib in improving SM symptoms in patients with SM has shown positive mid-stage results.